<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100066">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01801917</url>
  </required_header>
  <id_info>
    <org_study_id>CBAF312X2205</org_study_id>
    <nct_id>NCT01801917</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of BAF312 in Patients With Polymyositis</brief_title>
  <official_title>A Multi-centre Double-blind, Placebo Controlled, Proof of Concept Study to Evaluate the Efficacy and Tolerability of BAF312 in Patients With Polymyositis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the efficacy, safety and tolerability of BAF312 administered orally
      in patients with clinically active polymyositis and also in patients with polymyositis who
      have shown inadequate response to corticosteroids and or DMARDs (disease modifying
      antirheumatic drugs).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined efficacy endpoint: Manual Muscle Testing (MMT) and serum creatine kinase (CK) levels, or other enzymes, or MRI/biopsy if enzymes are normal.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessment of preliminary clinical efficacy of 2mg and 10mg BAF312 once daily using MMT of 24 muscles (MMT-24) and serum CK levels, or other enzymes, or MRI/biopsy if enzymes are normal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs), 6 minute walking distance test (MWD) and pharmacokinetics</measure>
    <time_frame>24 weeks for AEs and 12 weeks for 6MWD</time_frame>
    <description>Number of adverse events will be tabulated by body systems and treatment. Distance traveled over a 6 minute time period will be measured. Steady state pharmacokinetics of BAF312 will be characterized.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Polymyositis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAF312 2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAF312 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAF312 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAF312 10 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAF312</intervention_name>
    <arm_group_label>BAF312 2mg</arm_group_label>
    <arm_group_label>BAF312 10 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &quot;definite&quot; or &quot;probable&quot; for polymyositis at least three months before Baseline

          -  active disease as defined by elevated CK levels, or other enzymes, or MRI/biopsy if
             enzymes are normal, and persisting muscle weakness

          -  stable dose of corticosteroid for at least 2 weeks prior to Baseline and should not
             have received a medium or high dose in the last 8 weeks prior to study entry.

          -  patients treated with methotrexate must have been on a stable dose for at least 6
             weeks prior to Baseline.

        Exclusion Criteria:

          -  Patients with overlap polymyositis, late-stage polymyositis, or other types of
             myositis.

               -  Preexisting severe cardiac or pulmonary involvement, malignancy of any organ
                  system or significant eye diseases.

               -  Uncontrolled diabetes mellitus or diabetes complicated with organ involvement.

               -  Pregnant or nursing (lactating) women

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torono</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prague 2</city>
        <zip>128 50</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 19, 2017</lastchanged_date>
  <firstreceived_date>February 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polymyositis, Myositis, PM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Polymyositis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
